JanOne Inc. (NASDAQ:JAN) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 106,000 shares, a decrease of 57.8% from the September 15th total of 251,300 shares. Currently, 5.3% of the shares of the stock are sold short. Based on an average daily volume of 237,600 shares, the days-to-cover ratio is currently 0.4 days.
Several institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its holdings in JanOne by 33.1% in the 1st quarter. Citadel Advisors LLC now owns 31,969 shares of the company’s stock valued at $269,000 after purchasing an additional 7,945 shares in the last quarter. Renaissance Technologies LLC purchased a new position in JanOne in the 1st quarter valued at about $103,000. Geode Capital Management LLC purchased a new position in JanOne in the 2nd quarter valued at about $103,000. Vanguard Group Inc. lifted its holdings in JanOne by 65.5% in the 2nd quarter. Vanguard Group Inc. now owns 39,400 shares of the company’s stock valued at $307,000 after purchasing an additional 15,597 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in JanOne in the 1st quarter valued at about $175,000. Institutional investors and hedge funds own 5.42% of the company’s stock.
NASDAQ:JAN opened at $6.15 on Thursday. The company has a quick ratio of 0.44, a current ratio of 0.50 and a debt-to-equity ratio of 0.40. JanOne has a fifty-two week low of $3.49 and a fifty-two week high of $31.83. The stock has a market cap of $17.39 million, a PE ratio of -1.59 and a beta of 1.65. The firm’s fifty day simple moving average is $6.57 and its 200-day simple moving average is $7.25.
JanOne Company Profile
JanOne, Inc focuses on developing treatments for diseases that cause severe pain. It aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The firm also provides solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans.
Read More: What is the significance of the death cross?
Receive News & Ratings for JanOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JanOne and related companies with MarketBeat.com's FREE daily email newsletter.